moomoo ID:NaN
Log Out
Log in to access Online Inquiry

NervGen Pharma Upsizes Bought Deal Financing; Falls 11.1%

MT Newswires ·  {{timeTz}}

01:51 PM EDT, 11/05/2021 (MT Newswires) -- NervGen Pharma Corp., (NGEN.V), a clinical-stage biotech company, said Friday that it has increased the size of its $5 million bought deal offering.

Under the upsized deal terms, the underwriters have agreed to buy, on a "bought deal" basis, 3.2 million units at $2.50 per unit for gross proceeds of $8 million. The offering is expected to close by Nov. 12

The company's stock dropped 11.1% on last look on Friday in Canada.

Each unit will be comprised of one common share and one-half of one common share purchase warrant. In connection with the offering, the company has granted the underwriters an over-allotment option to buy an additional 480,000 units at the issue price which, if exercised in full, would increase the gross proceeds to about $9.2 million.

NervGen plans to use the net proceeds for continued development of lead drug candidate, NVG-291, and general corporate purposes.

Price: 2.48, Change: -0.31, Percent Change: -11.11

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.